Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to extend life in aggressive lung cancer

NCT ID NCT07055581

Recruiting now Disease control Sponsor: Qian Chu Source: ClinicalTrials.gov ↗

First seen Mar 29, 2026 · Last updated May 01, 2026 · Updated 7 times

Summary

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with limited-stage small-cell lung cancer live longer without the cancer growing. About 100 adults with this aggressive lung cancer will receive durvalumab plus chemo before radiation, then durvalumab alone after. The goal is to improve disease control and survival, though this is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER LIMITED STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450008, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SMALL CELL LUNG CANCER LIMITED STAGE